Kronos Bio Inc
KRON
Market Cap$44M
Close$
$1.68
132.6% upside
Current Fair Value
132.6% upsideUndervalued by 132.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $44.00 Million |
|---|---|
| Enterprise Value | $-13,785,625.00 |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-1.43 |
| Beta | 1.76 |
| Outstanding Shares | 60,344,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.51 |
|---|---|
| PEG | 0.92 |
| Price to Sales | - |
| Price to Book Ratio | 0.72 |
| Enterprise Value to Revenue | -1.4 |
| Enterprise Value to EBIT | 0.17 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -1.94 |
| Debt to Equity | 0.31 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Kronos Bio Inc
63 employeesKronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer. The company focuses on targeting dysregulated transcription factors ...